Compound kushen injection for multiple myeloma
A protocol of systematic review and meta-analysis
Xinwei Yang, MD, Xiyun Zhao, MD, Xiaoxia Wang, MD

1. Introduction

Multiple myeloma (MM), a complex and serious disease results from a proliferation of plasma cells often accompanied with osteolytic lesions, renal failure, anemia, and hypercalcemia, is the second most frequent hematologic malignancy around the world, accounted for approximately 10% of all hematologic malignancies.[1] In Western countries, the incidence is about 5.6 cases per 100,000 people, with a median age at diagnosis being 70 years and a third of patients over age 75.[2] Although MM currently remains an incurable malignancy, the treatments for MM has been greatly increased in the last decade, with novel proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs). And monoclonal antibodies now are being incorporated in treatment regimens, which have considerably improved progression-free survival (PFS) and overall survival (OS) of MM.[3–5] More and more patients with MM benefit from these new treatments. However, chemotherapy, especially high-dose chemotherapy, both PIs and IMiDs have different adverse events (AEs) for patients with MM.[6–8] These AEs can usually lower the quality of life and increase burden of patients. According to available evidence, for example, the combination of traditional Chinese medicine and chemotherapy has a promising clinical effect on patients with MM prolonging the patient’s life and improving the quality of life.[9,10] Compound kushen injection (CKJ) as a Chinese patent medicine was approved for treating cancer, inflammatory disease, and pain, etc. by the State Food and Drug Administration of China. CKJ consists of the following 2 Chinese herbs: sophora flavescens and polygonum sibiricum. The combination of the 2 Chinese herbs promotes eliminating stagnation stop pain, strengthens and consolidates body resistance, clears heat, and removes toxicity.[11] A alkaloids, fatty acids, and phenolic acids, are the main active compounds in CKJ, and CKJ has been widely used in the adjuvant treatment of severe diseases such as non–small cell lung cancer, primary liver cancer, digestive tract cancer, MM and malignant pleural effusion.[12–14] Given that both the number and quality of clinical trials using CKJ to treat MM have improved considerably in recent years, we sought to assess its efficacy and safety through a meta-analysis.

2. Methods

The content of this protocol follows the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) recommendations.[15] This review has been registered on the International
Prospective Register of Systematic Reviews with the identification number CRD42019133414. If protocol amendments occur, the dates, changes, and rationales will be tracked in the International Prospective Register of Systematic Reviews.

2.1. Criteria for inclusion and exclusion in the present review

2.1.1. Types of participants. Patients who aged 18 years or older were diagnosed MM by pathology or cytology, regardless of whether the patient has received treatment before. There are no restrictions on gender, race, etc. Patients accompanied by other malignant tumor or non-primary MM will not include.

2.1.2. Types of interventions. CKJ maintenance therapy vs placebo, or CKJ combined others treatments (such chemotherapy, radiotherapy, etc.) vs others treatments (others treatments of placebo, or CKJ combined others treatments (such chemotherapy).

2.1.3. Types of outcome. Outcomes of this meta-analysis will include overall response (OR), complete response (CR), 3-year OS, 3-year PFS and treatment-related AEs. OS is defined as the time from the date of randomization until disease progression or death. As for AEs, we will analyze the Grade 3 or 4 hematological and nonhematological toxicity.

2.1.4. Types of studies. Randomized controlled trials (RCTs) of CKJ for MM will be included to pool and review in this study. Non-RCTs, observational studies, qualitative studies, and laboratory studies will not be considered.

2.2. Search strategy

Search strategy will be performed on 6 electronic databases: PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Wangfang and Chinese Biomedical Literature Database. The MeSH search and text word will be used with the terms related to MM and compound kushen. We plan to use these databases from inception to April 2019, and the publications language will be restricted as English and Chinese. The search strategy is shown in Table 1 that taking PubMed as an example, and will be modified for other databases use if necessary. Other potentially eligible studies will also be manually searched the reference lists from the trials identified.

2.3. Study selection

All initial records from six electronic databases will be imported into the EndNoteX8 software (Thomson Reuters [Scientific] LLC, Philadelphia, PA). First, the titles and abstracts of all records will be reviewed independently by 2 reviewers. Then, full text of all potentially relevant articles will be retrieved to make the final decision. Any conflict will be resolved by discussion. A flow diagram will be used to describe the process of RCTs selection (Fig. 1).

2.4. Data collection

We plan to extract the following items from the included RCTs:

(i) General characteristics: author, year of publication, country where the study was performed, funding, study duration, contact details of the authors and identifiers;

(ii) Specific trial characteristics: sequence generation, allocation sequence concealment, blinding, incomplete outcome data, and selective outcome reporting, participants (total number, setting, age, sex, country, diagnostic criteria for MM, etc.), details of all experimental and control interventions (manufacturer of the drugs, dosages, medication route, duration of treatment, etc.), outcomes (OR, CR, OS, PFS, AEs);

(iii) We are also going to collect key conclusions, comments, and any explanations provided for unexpected findings by the study authors if applicable.

The steps of data collection: First, data extraction form will be designed based on previously identified items by our team; Second, 1 to 5 included studies will be pre-extracted, the forms shall be continually modified until the final data extraction form complete; Third, we shall contact the lead authors of included studies if there are issues to be clarified. Two reviewers will independently extract data from each included study. Different opinions will be resolved through discussion or consult the third part.

2.5. Quality assessment, risk of bias, and evidence profile

All data will be checked for internal consistency, and disagreements also be resolved by discussion. The quality of each clinical trial will be evaluated using the modified Jadad quality scores, including the presence of randomization, allocation concealment, blinding, and withdrawal/dropout. A general quality score was assigned to each study as follows: low quality studies (1–3), and high quality studies (4–5).

The risk of publication bias will be assessed by applying the funnel plot and Egger test. Evidence of asymmetry from Egger test will be considered to be significant at \( P < .1 \), and the graphical representation of 90% confidence bands is presented.

The quality of the evidence obtained for the primary endpoints will be assessed in agreement with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system.

| Table 1 |
|---|
| Searching strategy in PubMed. |
| Serial Number | Strategy |
| #1 | “Multiple Myeloma”[Mesh] OR “multiple myeloma”[Title/Abstract] OR “multiple myelomas”[Title/Abstract] OR “plasma-cell myeloma”[Title/Abstract] OR “plasma-cell myelomas”[Title/Abstract] OR myelomatosi[Title/Abstract] OR myelomatosis[Title/Abstract] OR “plasma cell myeloma”[Title/Abstract] OR “plasma cell myelomas”[Title/Abstract] OR “kahler disease”[Title/Abstract] OR “kahler diseases”[Title/Abstract] OR “myeloma multiple”[Title/Abstract] OR “myelomas multiple”[Title/Abstract] OR “myeloma-multiple”[Title/Abstract] OR “myeloma-multiples”[Title/Abstract] |
| #2 | “Fufangkushen”[Title/Abstract] OR “compound kushen injection”[Title/Abstract] OR CKJ[Title/Abstract] OR Fu-fang-ku-shen[Title/Abstract] OR Fu-fang-ku-shen[Title/Abstract] OR “Fu-fang-ku-shen”[Title/Abstract] OR Fu-fang ku shen[Title/Abstract] |
| #3 | #1 AND #2 |
2.6. Data synthesis

Statistical analyses will be performed using Review Manager 5.3 statistical software (Cochrane Collaboration, Denmark). The outcomes will be presented as the relative risk, mean difference or standardized mean difference and its 95% confidence interval (95% CI). The statistical significance will be assessed for \( P < .05 \), and moderate to high levels of heterogeneity will be considered if \( I^2 > 50\% \). A fixed effects model will be used if no statistical heterogeneity across the studies; otherwise, the random effects model will be considered.

2.7. Subgroup analysis

If sufficient studies are available, we are going to conduct subgroup analyses to explore the difference ages, doses, tumor staging, etc.

3. Discussion

Tradition Chinese medicine injection has been widely used in cancer, which effectiveness has been confirmed. However, the efficacy and safety of CKJ for MM is unclear. Therefore, we believe the results of this meta-analysis will provide some references for clinicians and researcher.

Acknowledgments

We thank Ming Liu, Lanzhou university basic medical college, for registered this review on the International Prospective Register of Systematic Reviews.

Author contributions

Conceptualization: Xinwei Yang, Xiaoxia Wang
Funding acquisition: Xiuyuan Zhao.
Methodology: Xinwei Yang, Xiuyuan Zhao
Methodology: Xiuyuan Zhao.
Project administration: Xinwei Yang, Xiaoxia Wang

References

[1] Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860–73.
[2] Altekruse SF KC, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; 2010.
[3] Baljevic M, Orlowski RZ. Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol 2019;15:459–73.
[4] Andhavarapu S, Roy V. Immunomodulatory drugs in multiple myeloma. Expert Rev Hematol 2013;6:69–82.
[5] Eckhart E, Hewitt R, Liedtke M. B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma. Immunotherapy 2019;11:801–11.
[6] Cornell RF, Ky B, Weiss BM. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol 2019;23:1–4.
[7] Aguiar PM, de Mendonça Lima T, Colleoni GWB, et al. Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses. Crit Rev Oncol Hematol 2017;113:195–212.
[8] Sun CY, Li JY, Chu ZB, et al. Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis. Biosci Rep 2017;37:1–8.
[9] Huang S, Pan W, Liu P, et al. Compound kushen injection combined with platinum chemotherapy drugs in the treatment of advanced gastric carcinoma: a systematic review and meta-analysis (Chinese). China J Chin Mater Med 2011;36:3198–202.
[10] Tian J, Ge L, Lou L, et al. Efficacy and safety of CF chemotherapy combined with traditional Chinese medicine injection in the treatment of breast cancer: a Network meta-analysis and sequential trial analysis (Chinese). Chin Gen Pract 2016;19:3326–35.
[11] Ma Y, Zhang Q, Wang Z, et al. Research progress of compound Kushen injection (Chinese). Chin J Exp Trad Med Formul 2012;18:342–5.
[12] Lin L, Zhou D, Chen Y, et al. Antitumor Effect of Compound Kushen Injection on Lung Cancer and Liver Cancer Cells (Chinese). Trad Chin Drug Res Clin Pharmacol 2009;20:21–3.
[13] Li C, Zhang Z, Shi Y. Clinical application of compound Kushen injection (Chinese). J Dis Monit Control 2010;04:330–2.
[14] Zhang W, Yang X. Clinical study of compound Kushen injection combined with chemotherapy in the treatment of multiple myeloma (Chinese). J Trad Chin Med Univ Hunan 2010;30:68–9.

[15] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.

[16] Booth A, Clarke M, Dooley G, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev 2012;1:2.

[17] Trotti A. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176–81.

[18] Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–2.

[19] Calzetta L, Rogliani P, Matera MG, et al. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest 2016;149:1181–96.

[20] Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction–GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383–94.

[21] Cazzola M, Calzetta L, Rogliani P, et al. Impact of doxofylline in COPD: a pair-wise meta-analysis. Pulm Pharmacol Ther 2018;51:1–9.